Improving Glucocorticoid Therapy in Leukemia
Improving Glucocorticoid Therapy in Leukemia
批准号:
278420
负责人:
Spaner David E
金额:
$27.47万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-03-01 至 2016-03-01
中文摘要
慢性淋巴细胞白血病或CLL是加拿大最常见的白血病类型。这种血癌不能用化疗治愈。糖皮质激素或类固醇是另一种治疗方法,可以帮助肿瘤细胞产生耐药性的患者
英文摘要
Chronic Lymphocytic Leukemia or CLL is the most common type of leukemia in Canada. This blood cancer cannot be cured with chemotherapy. Glucocorticoids, or steroids, are another form of treatment that can help patients whose tumor cells develop resistance
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the role of type 1 interferon in resistance to cancer immunotherapy
-
批准号:364090
-
项目类别:Operating Grants
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Spaner David E
-
依托单位:
Targeting Interferon-beta in leukemia immunotherapy
-
批准号:354690
-
项目类别:Operating Grants
-
资助金额:$33.44万
-
财政年份:2016
-
负责人:Spaner David E
-
依托单位:
Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia
-
批准号:170526
-
项目类别:Operating Grants
-
资助金额:$27.73万
-
财政年份:2008
-
负责人:Spaner David E
-
依托单位:
海外基金